Amer Overseas Gp Ltd (AOREF) 800.0000 $AOREF American

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amer Overseas Gp Ltd (AOREF) 800.0000 $AOREF

American Overseas Group Limited Announces Resignation of Director
GlobeNewswire - Fri Dec 18, 3:30PM CST
American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets:AOREF.PK) ("AORE" today announced that Steven J. Tynan has resigned as Chairman of the Board of Directors of American Overseas Group Limited and two of its wholly owned subsidiaries, Orpheus Group Limited and American Overseas Reinsurance Company Limited. Mr. Tynan has been a Director of AORE since 1998 and Chairman since 2001. The Board is thankful for Mr. Tynan's service and leadership over the past 14 years. Mr. Tynan will remain a consultant to the Company.

American Overseas Group Limited Announces Dividend on Its Class B Preference Shares
GlobeNewswire - Fri Nov 06, 3:30PM CST
American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets:AOREF.PK) ("AORE" today announced that the Board of Directors of its wholly owned subsidiary, American Overseas Reinsurance Company Limited ("the Company", declared a dividend on its Class B preference shares of $1,569.00 per Class B preference share. The dividend will be payable on December 16, 2015, to Class B preference shareholders of record on December 9, 2015.

RESULTS OF OPERATIONS THROUGH JUNE 30, 2015 - American Overseas Group Limited Announces Net Income of $7.0 Million and Operating Loss of $9.4 Million Through June 30, 2015
GlobeNewswire - Mon Sep 28, 3:30PM CDT
American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets: AOREF.PK) ("AOG" or the "Company" today reported consolidated net income of $7.0 million, or $165.63 per diluted share, for the six months ended June 30, 2015. This compares to consolidated net income of $7.0 million, or $254.83 per diluted share, for the six months ended June 30, 2014. On October 28, 2014, the Company acquired Orpheus Group Ltd. ("OGL" for a combination of common stock and senior notes. As a result, the previously reported 2014 consolidated balance sheet, consolidated statement of operations, consolidated statement of comprehensive income, and the consolidated statement of cash flows of the Company have been adjusted to consolidate the operations of the Company with OGL. The results for the first six months of 2015 were impacted by fair value adjustments of $3.4 million and unrealized gains in credit derivatives of $15.3 million. The results for the first six months of 2014 were impacted by fair value adjustments of $11.4 million and unrealized losses in credit derivatives of $2.4 million. Book value per share at June 30, 2015 was $1,532.61.

American Overseas Group Limited Issues Supplement Information and Updated Earnings Release Regarding Net Income and Operating Loss for the Year Ended December 31, 2014
GlobeNewswire - Fri Jul 03, 4:47PM CDT
American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets:AOREF.PK) ("AOG" or the "Company" today reported consolidated net income of $38.4 million, or $1,797.58 per diluted share, for the year ended December 31, 2014. This compares to a consolidated net loss of $0.3 million, or $16.39 per diluted share, for the year ended December 31, 2013. The 2013 financial statements of AOG have been restated to reflect the fact that AOG and Orpheus Group Ltd. came under common voting control on June 26, 2013, and to include the results of Orpheus Group Ltd. from that date. The results for 2014 were impacted by fair value adjustments of $22.8 million and unrealized gains in credit derivatives of $18.2 million. Book value per share at December 31, 2014 was $1,327.28.

American Overseas Group Limited Announces Net Income Of $38.4 Million and Operating Loss of $3.2 Million for the Year Ended December 31, 2014
GlobeNewswire - Tue Jun 30, 4:07PM CDT
American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets:AOREF.PK) ("AOG" or the "Company" today reported consolidated net income of $38.4 million, or $1,797.58 per diluted share, for the year ended December 31, 2014. This compares to a consolidated net loss of $0.3 million, or $16.39 per diluted share, for the year ended December 31, 2013. The 2013 financial statements of AOG have been restated to reflect the fact that AOG and Orpheus Group Ltd. came under common voting control on June 26, 2013, and to include the results of Orpheus Group Ltd. from that date. The results for 2014 were impacted by fair value adjustments of $22.8 million and unrealized gains in credit derivatives of $18.2 million. Book value per share at December 31, 2014 was $1,327.28.

American Overseas Group Limited Announces New Directors at Its Subsidiaries
GlobeNewswire - Mon Dec 22, 5:19PM CST
American Overseas Group Limited (BSX:AORE.BH) (Pink Sheets:AOREF.PK) ("AOG" or the "Company" today announced the appointment of directors to its subsidiary companies.

American Overseas Group Limited Announces Acquisition of Orpheus Group Ltd.
GlobeNewswire - Wed Oct 29, 4:30PM CDT
American Overseas Group Limited (BSX:AORE.BH) (Pink Sheets:AOREF.PK) ("AOG" or the "Company" today announced the acquisition of Orpheus Group Ltd. (together with its subsidiaries, "Orpheus", formerly the principal shareholder of the Company, for a combination of common stock and senior notes. Following the transaction, the Company's outstanding common shares increased from 27,492 shares to 42,914 shares, net of treasury stock. The Company also issued approximately $43.9 million of senior notes in connection with the transaction.

American Overseas Group Limited Announces Completion of Reverse Stock Split, Effective October 15, 2014
GlobeNewswire - Fri Oct 24, 3:49PM CDT
American Overseas Group Limited (BSX:AORE.BH) (Pink Sheets:AOREF.PK) ("AOG" or the "Company" today announced the completion of the reverse stock split of the Company's issued common shares (the "Consolidation", effective on the Bermuda Stock Exchange close of market in Bermuda on October 15, 2014 (the "Effective Time".

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading